Table 5.
Number of treatment changes during the patients' disease course stratified by disease type and disease activity
| Number of changes | ||||||||
|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | 5 | |||
| R‐R disease (288, 68.57%) | R‐R (276; 95.84%) | A‐T | 7 | 11 | 8 | 1 | 0 | 1 |
| A‐NT | 1 | 2 | 0 | 0 | 0 | 0 | ||
| NA‐T | 96 | 66 | 26 | 13 | 1 | 0 | ||
| NA‐NT | 3 | 1 | 1 | 0 | 0 | 0 | ||
| Progressive disease (132, 31.43%) | PP (30; 22.73%) | A‐NP | 1 | 0 | 0 | 1 | 0 | 0 |
| A‐P | 2 | 0 | 1 | 0 | 0 | 0 | ||
| NA‐NP | 4 | 0 | 1 | 0 | 0 | 0 | ||
| NA‐P | 7 | 1 | 0 | 0 | 0 | 0 | ||
| SP (102; 77.27%) | A‐NP | 1 | 3 | 2 | 0 | 0 | 0 | |
| A‐P | 4 | 5 | 5 | 2 | 0 | 0 | ||
| NA‐NP | 15 | 15 | 6 | 6 | 0 | 0 | ||
| NA‐P | 10 | 5 | 5 | 1 | 0 | 0 | ||
In the majority of patients with whom no disease activity was seen, it was achieved with either their first or second disease modifying treatment (NA‐T and NA‐NP groups within the R‐R and progressive disease course, respectively).
Abbreviations: A‐NP, active–not progressive (patient showing disease without progression); A‐NT, active–not treated (patients showing disease activity without receiving treatment); A‐P, active–progressive (patient showing disease and progression at the same time); A‐T, active–treated (patients showing disease activity despite receiving treatment); CIS, clinically isolated syndrome; NA‐NP, not active–not progressive (patient not showing disease activity nor progression); NA‐NT, not active–not treated (patient not showing disease activity without receiving treatment); NA‐P, not active–progressive (patient not showing disease activity while showing progression); NA‐T, not active–treated (patient not showing disease activity while receiving treatment); PP, primary progressive disease; R‐R, relapsing–remitting; SP, secondary progressive disease.